Depression, Anxiety, and Risk of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Longitudinal Study
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae256 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Iris T Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Metabolic Syndrome, Depression, Anxiety. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Context
Patients with polycystic ovary syndrome (PCOS) are at high risk of depression, anxiety, and metabolic syndrome (MetSyn), a key predictor of cardiovascular disease. The impact of depression and/or anxiety on MetSyn is unknown in this population.
Objective
To compare the risk of developing MetSyn in patients with PCOS with and without a history of depression and/or anxiety.
Methods
Retrospective longitudinal cohort study (2008-2022) with median follow-up of 7 years at a tertiary care ambulatory practice. Patients with hyperandrogenic PCOS and at least 2 evaluations for MetSyn ≥3 years apart (n = 321) were included. The primary outcome was risk of developing MetSyn. We hypothesized that this risk would be higher with a history of depression and/or anxiety.
Results
At the first visit, 33.0% had a history of depression and/or anxiety, with a third prescribed antidepressants or anxiolytics. Depression and/or anxiety increased risk of developing MetSyn during the study period (adjusted hazard ratio [aHR] 1.45, 95% CI 1.02-2.06, P = .04) with an incidence of MetSyn of 75.3 compared with 47.6 cases per 100 person-years among those without (P = .002). This was primarily driven by depression (aHR 1.56, 95% CI 1.10-2.20, P = .01).
Conclusion
Patients with PCOS and depression and/or anxiety have a high risk of developing MetSyn, with a stronger association between depression and MetSyn. Our findings highlight the urgent need for guideline-directed screening for depression and anxiety at time of diagnosis of PCOS as well as screening at subsequent visits to facilitate risk stratification for metabolic monitoring and early intervention in this high-risk group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Iris T Lee, Stefanie Hinkle
Zitieren
APA
Lee, I. T., Rees, J., King, S., Kim, A., Cherlin, T., Hinkle, S., Mumford, S. L., & Dokras, A. (2025). Depression, Anxiety, and Risk of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Longitudinal Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae256
Vancouver
Lee IT, Rees J, King S, Kim A, Cherlin T, Hinkle S, et al. Depression, Anxiety, and Risk of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Longitudinal Study. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae256
BibTeX
@article{Lee2025,
author = {Lee, Iris T and Rees, John and King, Shakira and Kim, Anne and Cherlin, Tess and Hinkle, Stefanie and Mumford, Sunni L and Dokras, Anuja},
title = {Depression, Anxiety, and Risk of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Longitudinal Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae256}
}
EUVIMED